Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2002-03-05
2008-09-09
Puttlitz, Karl (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S194000, C564S200000, C564S202000, C564S211000, C514S613000
Reexamination Certificate
active
07423177
ABSTRACT:
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4356108 (1982-10-01), Schwab et al.
patent: 4873313 (1989-10-01), Crawford et al.
patent: 5202424 (1993-04-01), Vlassara et al.
patent: 5585344 (1996-12-01), Vlassara et al.
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5922770 (1999-07-01), Peschke et al.
patent: 5939526 (1999-08-01), Gaugler et al.
patent: 6100098 (2000-08-01), Newkirk
patent: 6613801 (2003-09-01), Mjalli et al.
patent: 7067554 (2006-06-01), Mjalli et al.
patent: 2004/0097407 (2004-05-01), Mjalli et al.
patent: 2 005 674 (1979-04-01), None
patent: 7-51550 (1995-06-01), None
patent: WO 95/09838 (1995-04-01), None
patent: WO 95/35279 (1995-12-01), None
patent: WO 96/32385 (1996-10-01), None
patent: WO 97/22618 (1997-06-01), None
patent: WO 97/26913 (1997-07-01), None
patent: WO 97/39121 (1997-10-01), None
patent: WO 9739125 (1997-10-01), None
patent: WO 98/22138 (1998-05-01), None
patent: WO 98/33492 (1998-08-01), None
patent: WO 99/07402 (1999-02-01), None
patent: WO 99/18987 (1999-04-01), None
patent: WO 99/25690 (1999-05-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/54485 (1999-10-01), None
patent: WO 00/20458 (2000-04-01), None
patent: WO 00/20621 (2000-04-01), None
patent: WO 01/12598 (2001-02-01), None
Chem. Abst. 116:58986 (1992).
Dobrev et al., Khimicheski Fakultet (1978), vol. Date 1975-1976, 70, Pt. 1, 201-7, CAS online abstract retrieved Apr. 16, 2007 from STN, Columbus, OH, USA.
Albercio, F. & Carpino, L.A., “Coupling Reagents and Activation”Methods in Enzymology289:104-126, Academic Press, San Diego (1997).
Barton, J.W., “In Protection of N-H Bonds and NR3”Protective Groups in Organic Chemistry, J.F.W. McOmie, ED., Plenum Press, New York, NY (1973).
Berge, S.M., et al., “Pharmaceutical Salts”Journal of Pharmaceutical Sciences66:1-19 (1977).
Chitaley, K., et al., “Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway”Nature Medicine7:119-122 (2002).
Degenhardt, T.P., et al., “Chemical Modification of Proteins by Methylglyoxal”Cell Mol. Biol., 44:1139-1145 (1998).
Dyer, D.G., et al., “Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging”J. Clin. Invest., 91:2463-2469 (1993).
Dyer, D.G., et al., “Formation of Pentosidine during Nonenzymatic Browning of Proteins by Glucose”J. Biol. Chem., 266:11654-11660 (1991).
Greene, T.W., “Protection for the Amino Group”Protective Groups in Organic Synthesis, John Wiley and Sons ,New York, NY, Chapter 7 (1981).
Hammes, H.P., et al., “Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidation Product Nε-(Carboxymethyl) Lysine Independently of Glycohaemoglobin Concentrations” Diabetologia, 42:603-607 (1999).
Hoffman, M.A., et al., “RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides”Cell, 97:889-901 (1999).
Hori, O., et al., “The Receptor for Avanced Glycation End Products (RAGE) is a Cellular Binding site for Amphoterin”J. Biol. Chem., 270:25752-761 (1995).
Huttunen, H.J., et al., “Receptor for Advanced Glycation End Products (RAGE)- Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways”J. Biol. Chem. 274(28):19919-24 (1999).
Kumar, S.R., et al., “RAGE at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloidβ1-40Peptide”Neurosci. Program, 141-#255.19 (2000).
Leder, A. et al., “v-HA-rasTransgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid”Proc. Natl. Acad. Sci., USA, 87:9178-9182 (1990).
Li, J. et al., “Sp1-Binding elements in the Promoter of RAG Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells.”J. Biol. Chem., 273:30870-30878 (1998).
Li, J. et al., “Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products,”J. Biol. Chem., 272:16498-16506 (1997).
Lugering, N. et al., “The Myeloic Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function” Eur. J. Clin. Invest., 25:659-664 (1995).
Miyata, T. et al., “β2-Microglobulin Modified with Advanced Glycation End Products Is a Major Component of Hemodialysis-Associated Amyloidosis”J. Clin. Invest., 92:1243-1252 (1993).
Miyata, T. et al., “The Receptor for Advanced Glycation End Products (RAGE) Is a Central Mediator of the Interaction of AGE-β2Microglobulin with Human Mononuclear Phagocytes Via an Oxidant-Sensitive Pathway”J. Clin. Invest., 98:1088-1094 (1996).
Neeper, M., et al., “Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins”J. Biol. Chem., 267:14998-15004 (1992).
Parkkinen, J. et al., “Amphoterin, the 30-kDa Protein in a Family of HMG1-Type Polypeptides”J. Biol Chem., 268:19726-19738 (1993).
Rammes, A. et al., Myeloid-Related Protein (MRP) 8 and MRP 14, Calcium-Binding Proteins of the S100 Family, Are Secreted by Activated Monocytes via a Novel, Tubulin-Dependent PathwayJ. Biol. Chem., 272:9496-9502 (1997).
Rauvala, H. et al., “Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons”J. Biol. Chem., 262:16625-16635 (1987).
Reddy, S. et al., “Nε-(Carboxymethyl) Lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue Proteins”Biochem., 34:10872-10878 (1995).
Schafer, B.W., et al., “The S100 Family of EF-Hand Calcium-Binding Proteins: Functions and Pathology”TIBS, 21:134-140 (1996).
Schleicher, E.D., et al., “Increased Accumulation of the Glycoxidation Product Nε-(Carboxymethyl) Lysine in Human Tissues in Diabetes and Aging”J. Clin. Invest., 99(3):457-468 (1997).
Schmidt, A.M. et al., “The Dark Side of Glucose”Nature Med., 1:1002-1004 (1995).
Schmidt, A.M., et al., “The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therpy of Diabetic Complications:”Supplement to Circulationvol. 96, #194 (1997).
Taguchi, A. et al., “Blockade of RAGE—Amphoterin Signalling Suppresses Tumour Growth and Metastases”Nature, 405:354-360 (2000).
Tanaka, N., et al., “The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear FactorκB, and by 17β-Estradoil through Sp-1 in Human Vascular Endothelial Cells”J. Biol. Chem., 275:25781-25790 (2000).
Teillet et al., “Food Restriction Prevents Advanced Glycation End Product Accumulation and Retards Kidney Aging in Lean Rats”J. Am. S
Andrews Robert C.
Gopalaswamy Ramesh
Mjalli Adnan M. M.
Wysong Chris
Puttlitz Karl
Rollins Samuel B.
TransTech Pharma, Inc.
LandOfFree
Carboxamide derivatives as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxamide derivatives as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxamide derivatives as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3975916